Differences in external price referencing in Europe-A descriptive overview

Health Policy

Volumn 104, Issue 1, 2012, Pages 50-60

  Leopold, Christine ^a,b   Vogler, Sabine ^a   Mantel Teeuwisse, A K ^b   de Joncheere, Kees ^c   Leufkens, H G M ^b   Laing, Richard ^c  

^a GESUNDHEIT ÖSTERREICH GMBH   (Austria)

^b UTRECHT UNIVERSITY   (Netherlands)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Europe; External price referencing; Pharmaceutical policy; Pricing

Indexed keywords

ARTICLE; DRUG COST; DRUG LEGISLATION; EUROPE; HUMAN; INCOME; MEDICOLEGAL ASPECT; METHODOLOGY; POLICY; PROSPECTIVE PRICING; REIMBURSEMENT;

COSTS AND COST ANALYSIS; ECONOMIC COMPETITION; ECONOMICS, PHARMACEUTICAL; EUROPE; HEALTH POLICY; HUMANS; PHARMACEUTICAL PREPARATIONS; REIMBURSEMENT MECHANISMS;

EID: 83555163611     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2011.09.008     Document Type: Article

References (29)

1. Vogler S., et al. Pharmaceutical Pricing and Reimbursement Information (PPRI): final report 2007, DG Health and Consumer Protection of the European Commission, Luxembourg, Available online at: http://ppri.goeg.at.
2. Docteur E., et al. Pharmaceutical pricing polices in a global market 2007, OECD Health Policy Studies, Paris.
3. Seiter A., et al. Access to medicines and the innovation dilemma - Can pharmaceutical multinationals be good corporate citizens?. Business Ethics of Innovation Ethics of Science and Technology Assessment 2007, 31:89-100.
4. Vandergrift M., Kanavos P. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada. Health Policy 1997, 41(September (3)):241-260.
5. Scherer F.M. The pharmaceutical industry - price and progress. The New England Journal of Medicine 2004, 927-932.
6. Amemiyat Advanced econometrics 1985, Harvard University Press, Cambridge, MA.
7. Marquis M.S., Phelps C.E. Price elasticity and adverse selection in the demand for supplementary health insurance. Economic Inquiry 1987, 25:299-313.
8. Morrisey M. Price sensitivity in health care: implications for health care policy 1992, The National Federation of Independent Business Foundation, Washington D.C.
9. Espin J, Rovira J. External Price Referencing. WHO/HAI project on medicines prices and availability. Policy paper, 2010 (unpublished).
10. Rosian I., Vogler S. Internationale arzneimittelpreise. Eine meta-analyse 2004, öBIG, Vienna.
11. Danzon P.M., Chao L.W. Cross-national price differences for pharmaceuticals: how large, and why?. Journal of Health Economics 2000, 19:159-195.
12. Mrazek M. Comparative approaches to pharmaceutical price regulation in the European Union. Croatian Medical Journal 2002, 43(4):453-461.
13. Stargardt T., Schreyögg J. The impact of cross-reference pricing on pharmaceutical prices - manufacturers' pricing strategies and price regulation 2006, Department of Health Care Management, University of Technology, Berlin.
14. Pharmaceutical Price Information (PPI) Service. Gesundheit österreich GmbH/Austrian Health Institute. Available online at: http://ppi.goeg.at/.
15. Norwegian Medicines Agency (NOMA). Available online at: http://www.legemiddelverket.no/.
16. Pharma Pricing and Reimbursement Germany: 2009 impact of voluntary discount agreements & 2010 trends. IMS Health 2010, 15(July (7)):200-203.
17. Pharma Pricing and Reimbursement Netherlands: latest market developments. IMS Health 2010, 15(November (11)):326-328.
18. Seiter A. A practical approach to pharmaceutical policy 2010, The World Bank.
19. Windmeijer F., et al. Pharmaceutical promotion and GP prescription behavior. Health Economics 2006, 15:5-18.
20. Merkur S., Mossialos E. A pricing policy towards the sourcing of cheaper drugs in Cyprus. Health Policy 2007, 81:368-375.
21. Vogler S., Habl C., et al. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Croatian Medical Journal 2011, 183-197.
22. Filko M., Szilagyiova P. The Slovak experience in the international price benchmarking for prescription drugs. Value in Health 2009, 12(7):229-230.
23. Danzon P.M., Wang Y., et al. The impact of price regulation on the launch delay of new drugs. Journal of Health Economics 2005, 14(3):269-292.
24. Ellison S., et al. Coordinating on lower prices: pharmaceutical pricing under political pressure 2004, Haas School of Business, U.C. Berkeley, Mimeo.
25. Kyle M. Pharmaceutical price controls and entry strategies 2004, Fuqua School of Business, Duke University, Mimeo.
26. Kyle M. The role of firm characteristics in pharmaceutical product launches 2004, Fuqua School of Business, Duke University, Mimeo.
27. European Commission. The High Level Group on innovation and provision of medicines. Recommendations for action, May 2002, p. 16. Available online at: http://ec.europa.eu/enterprise/sectors/healthcare/files/phabiocom/docs/g10-medicines_en.pdf.
28. European Commission. A stronger European-based pharmaceutical industry for the benefit of the patient - a call for action, 2003, p. 15. Available online at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do%3Furi=COM%3A%202003%3A0383%3AFIN%3Aen%3APDF.
29. European Commission. Pharmaceutical sector inquiry, 2008. Available online at: (last accessed 20.12.10). http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/index.htm.